Equities analysts expect X4 Pharmaceuticals Inc (NASDAQ:XFOR) to post ($0.79) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for X4 Pharmaceuticals’ earnings. X4 Pharmaceuticals posted earnings per share of ($5.10) during the same quarter last year, which suggests a positive year-over-year growth rate of 84.5%. The company is expected to announce its next quarterly earnings report on Monday, August 12th.
On average, analysts expect that X4 Pharmaceuticals will report full year earnings of ($3.77) per share for the current financial year, with EPS estimates ranging from ($3.90) to ($3.64). For the next year, analysts forecast that the company will report earnings of ($3.80) per share, with EPS estimates ranging from ($3.84) to ($3.75). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow X4 Pharmaceuticals.
X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($6.67) earnings per share (EPS) for the quarter.
A hedge fund recently bought a new stake in X4 Pharmaceuticals stock. Polaris Venture Management Co. V L.L.C. purchased a new stake in X4 Pharmaceuticals Inc (NASDAQ:XFOR) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 311,492 shares of the company’s stock, valued at approximately $5,423,000. X4 Pharmaceuticals comprises 4.6% of Polaris Venture Management Co. V L.L.C.’s holdings, making the stock its 6th biggest holding. Polaris Venture Management Co. V L.L.C. owned about 2.51% of X4 Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 14.40% of the company’s stock.
Shares of NASDAQ XFOR traded up $0.48 during midday trading on Friday, reaching $14.63. 26,666 shares of the company traded hands, compared to its average volume of 53,321. The business’s 50-day moving average price is $15.30. X4 Pharmaceuticals has a 12 month low of $6.90 and a 12 month high of $29.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.59 and a current ratio of 1.59.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Further Reading: The components of the Stochastic Momentum Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.